Elanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S. Food and Drug Administration (FDA) has approved Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel ...

Animal health company Elanco (NYSE:ELAN ... in research and development to create innovative, patent-protected drugs for ...

Let’s take a look at how pharmaceuticals stocks fared in Q4, starting with Elanco (NYSE:ELAN). The pharmaceuticals sector is pivotal in the development, manufacturing, and distribution of drugs ...

Elanco is a global leader in animal health pharmaceutical products. The stock has struggled due to concerns about the launch of the company’s Zenrelia drug, which is a JAK inhibitor for dogs ...

Elanco Animal Health's stock declined 26%, but despite improved financials, high debt levels and limited growth opportunities make it a cautious investment. Fiscal 2024 saw slight revenue growth ...

Elanco has made progress in getting dermatology drug Zenrelia placed in roughly 8,000 US vet practices and has had a strong start with vet tech marketing and sampling to convert clinics.

Longevity drug developer Loyal and pain therapy manufacturer Elanco Animal Health are working with the organization to ...

Elanco Animal's Outlook Lags Street Expectations But Analyst Sees Time For Elanco's Commercial Investment To Payoff Elanco's Q4 revenue reached $1.02 billion, topping estimates, but EPS missed ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. It offers pet health products, such as ...